Medrobotics markets its Flex Robotic System for gastroenterology applications in Europe

Medrobotics Corp. today announced the first sale in Europe of their Flex® Robotic System for gastroenterology applications. The hospital, A.O. Universitaria Città della Salute e della Scienza di Torino, will be the first European facility to offer Scarfree interventional endoscopic procedures. Patients and physicians will both benefit from the System's crystal clear 3D visualization, robotic precision, platform stability, and potentially shorter procedure times.

"Colorectal cancer is the second leading cause of cancer deaths in Europe," said Samuel Straface, Ph.D., President and CEO of Medrobotics. "Patients with cancer and non-malignant lesions are treated by gastroenterologists and colorectal surgeons. The Flex® Robotic System offers physicians the possibility of treating patients more easily and less invasively than might otherwise be possible with traditional flexible endoscopes."

Medrobotics markets the Flex® Robotic System, the first and only robotic surgical platform providing Scarfree access to hard-to-reach anatomy in otolaryngology, colorectal and gastroenterology procedures. The award-winning Flex® Robotic System has been widely recognized including Best-in-Show at the 2016 Medical Design Excellence Awards (MDEA) and a Best New Product at the 2017 Edison Awards. For hospitals, the portability and ease of use of the Flex® Robotic System potentially offers more patients access to minimally invasive surgical options in the operating room, as well as endoscopy suite, which is not seen with other surgical systems.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes medication shows promise in reducing alcohol use